This brand name is authorized in United States
The drug RELYVRIO contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Sodium phenylbutyrate
UNII NT6K61736T - SODIUM PHENYLBUTYRATE
|
|
Sodium phenylbutyrate is a pro-drug and is rapidly metabolised to phenylacetate. Phenylacetate is a metabolically active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine which is then excreted by the kidneys. On a molar basis, phenylacetylglutamine is comparable to urea (each containing 2 moles of nitrogen) and therefore provides an alternate vehicle for waste nitrogen excretion. |
|
2
Ursodoxicoltaurine
UNII 60EUX8MN5X - TAURURSODIOL
|
|
|
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| RELYVRIO Powder for oral suspension | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 73063-035 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
